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 Orai1 is predominantly located in the heavy and light microsomes in rat liver 
 STIM1 is predominantly located in the heavy and light microsomes in rat liver 
 STIM1 interacts with peroxiredoxin-4 in heavy microsomes derived from liver 
 Peroxiredoxin-4 alters the susceptibility of STIM1 to inhibition by H2O2 
 
ABSTRACT 
Ca2+ entry through store-operated Ca2+ channels (SOCs) in the plasma membrane (PM) of 
hepatocytes plays a central role in the hormonal regulation of liver metabolism. SOCs are 
composed of Orai1, the channel pore protein, and STIM1, the activator protein, and are 
regulated by hormones and reactive oxygen species (ROS). In addition to Orai1, STIM1 also 
interacts with several other intracellular proteins. Most previous studies of the cellular 
functions of Orai1 and STIM1 have employed immortalised cells in culture expressing 
ectopic proteins tagged with a fluorescent polypeptide such as GFP. Little is known about the 












intracellular distribution of endogenous Orai1 and STIM1 in hepatocytes and to identify 
novel STIM1 binding proteins. Subcellular fractions of rat liver were prepared by 
homogenisation and differential centrifugation. Orai1 and STIM1 were identified and 
quantified by western blot. Orai1 was found in the PM (0.03%), heavy (44%) and light (27%) 
microsomal fractions, and STIM1 in the PM (0.09%), and heavy (85%) and light (13%) 
microsomal fractions. Immunoprecipitation of STIM1 followed by LC/MS or western blot 
identified peroxiredoxin-4 (Prx-4) as a potential STIM1 binding protein. Prx-4 was found 
principally in the heavy microsomal fraction. Knockdown of Prx-4 using siRNA, or 
inhibition of Prx-4 using conoidin A, did not affect Ca2+ entry through SOCs but rendered 
SOCs susceptible to inhibition by H2O2. It is concluded that, in hepatocytes, a considerable 
proportion of endogenous Orai1 and STIM1 is located in the rough ER. In the rough ER, 
STIM1 interacts with Prx-4, and this interaction may contribute to the regulation by ROS of 
STIM1 and SOCs. 
 
Abbreviations: [Ca2+]cyt, cytoplasmic free Ca
2+ concentration; Ca2+ext, extracellular Ca
2+; ER, 
endoplasmic reticulum; PM, plasma membrane; SERCA, sarco/endoplasmic reticulum (Ca2+ 
+Mg2+)ATP-ase; PMCA, plasma membrane (Ca2+ +Mg2+)ATP-ase; SOCE, store-operated 
Ca2+ entry;  SPCA, secretory pathway Ca2+ ATP-ase; SOC, store-operated Ca2+ channel; 
STIM, stromal interaction molecule; [Ca2+]ext, extracellular free Ca
2+ concentration; DBHQ, 
2,5-di-(tert-butyl)-1,4-benzohydro-quinone; GFP, green fluorescent protein; Prx-4, 
peroxiredoxin-4; TRPM2, transient receptor potential melastatin 2; PMSF, 
phenylmethylsulfonyl fluoride; ROS, reactive oxygen species; HRP, horse radish peroxidase.  

















Store-operated Ca2+ channels (SOCs) in the plasma membrane (PM), and Ca2+ entry 
through these channels (SOCE), play essential roles in the regulation by intracellular Ca2+ of 
cell growth, death and function in almost all animal cell types [1].  SOCE replenishes the ER 
Ca2+ stores during and after InsP3-mediated Ca
2+ release induced by hormones and other 
extracellular signals.  In some situations SOCE contributes directly to changes in the 
cytoplasmic free Ca2+ concentration ([Ca2+]cyt) induced by extracellular signals [1, 2].  In 
addition to hormonal signals, reactive oxygen species (ROS) can also alter SOCE in both 
normal and pathological conditions (reviewed in [3, 4]). Most SOCs are composed of Orai1 
polypeptides, which constitute the channel pore located in the PM, and STIM1 polypeptides 
located in the endoplasmic reticulum (ER), which activate Orai1 (reviewed in [1]). 
SOC activation is initiated by a decrease in the Ca2+ concentration in the lumen of a 
sub-region of the ER which is devoid of ribosomes and located in ER-PM junctions at the 
periphery of the cell [1, 5, 6]. This leads to the dissociation of Ca2+ from the luminal E, F 
hand-sterile alpha (EF-SAM) Ca2+ binding motif in the N-terminal of STIM1, conformational 
changes in STIM1, movement of STIM1 in the plane of the ER membrane, interaction of the 
cytoplasmic CRAC activation domain (CAD) in the C-terminal of STIM1 with Orai1 located 
in the PM, and formation of an active functional SOC [1, 7]. Functional SOCs are composed 
of a hexamer of Orai1 polypeptides and approximately 4 STIM1 polypeptides [1, 7]. It is 
generally thought that in order to achieve SOCE activation, Orai1 must be present in the PM 
and STIM1 in the peripheral ER, located in close proximity to the plasma membrane [1].  












numerous other intracellular proteins (reviewed in [8]). Some of these STIM1-binding 
proteins modulate the interaction of STIM1 with Orai1 or modulate other proteins involved in 
intracellular Ca2+ homeostasis, while others are involved in regulation of the microtubular 
network [8-10]. 
Most previous studies on the intracellular distribution of Orai1 and STIM1 have been 
conducted using immortalised cells in culture over-expressing ectopic Orai1 and STIM1 
tagged with a fluorescence peptide such as GFP, or variants of GFP [1, 11-16]. Much less is 
known about the distribution of endogenous Orai1 and STIM1 in situ. We have previously 
characterised SOCs in hepatocytes. These cells express functional SOCs with high selectivity 
for Ca2+, and channel properties essentially identical to those in lymphocytes and mast cells 
[17]. While each of the main isoforms of STIM and Orai has been detected in rat hepatocytes 
and in immortalised H4IIE rat liver cells, the expression of STIM2 is lower than that of 
STIM1, Orai2 is barely detectable, and expression of Orai3 is much lower than that of Orai1 
[18]. Previous studies, in which expression of STIM1 and Orai1 has been knocked down by 
siRNA, indicate that SOCs in rat hepatocytes and in H4IIE rat liver cells are principally 
composed of the STIM1 and Orai1 polypeptides [17, 19]. Our previous studies employing 
GFP- or Cherry-STIM1 have shown that, upon the release of Ca2+ from the ER, STIM1 forms 
puncta and moves to the PM [20, 21].  
The aims of this study were to investigate the intracellular distribution of endogenous 
Orai1 and STIM1 in hepatocytes and to seek to identify additional novel proteins which may 
modify the action of STIM1. The experiments have employed the preparation and analysis of 
subcellular fractions of rat liver. The bulk of the liver is composed of hepatocytes which are 
the principle cell type responsible for liver-specific functions [22].  Moreover, liver tissue 












high yields of each subcellular fraction can be obtained [23]. A subcellular fractionation 
approach, rather than an alternative one based on immunofluorescence and confocal imaging, 
was chosen since we and others have found that it is sometimes difficult to obtain antibodies 
against PM ion channel proteins such as Orai1 and members of the TRP family with 
sufficient specificity [24, 25]. Furthermore, we wanted to employ immunoprecipitation and 
LC/MS to identify new STIM1 binding partners. This strategy requires relatively large 
amounts of protein, which can be obtained by liver homogenisation and subcellular 
fractionation. 
2. Materials and methods 
2.1. Materials 
Phenylephrine was purchased from Sigma, St. Louis, MO USA; Conoidin A from the 
Cayman Chemical Company, whole serum (# R-1593-100) from Biosensis, Thebarton, South 
Australia; Protein A/G PLUS-Agarose immunoprecipitation reagent (#SC2003), normal mouse 
IgG (#SC-2025) and normal rabbit IgG (# sc-2027) from Santa Cruz Biotechnology, Dallas, 
Texas, USA, and protein ladders (markers) for western blot from BioRad Laboratories, New 
South Wales, Australia. The sources of the primary and secondary antibodies are listed in Table 
1. The sources of all other materials were as described previously [18, 26, 27]. 
2.2. Rat liver homogenisation 
Male Hooded Wistar rats weighing 250-350g, housed in the Flinders Medical Centre 
Animal Facility, were provided ad libitum access to food and water, with a lighting cycle of 
12 h. Animals received humane care, and the experimental protocols were conducted 
according to the criteria outlined in the “Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes” (National Health and Medical Research Council of 












by Lievrement et al. [28]. Rats were sedated with isoflurane then anesthetized by an 
intraperitoneal injection of ketamine (100 mg/kg body weight) and xylazine (8 mg/kg body 
weight). The homogenisation medium was composed of 250 mM sucrose, 5 mM HEPES-
KOH and 1 mM EGTA, adjusted to pH 7.4, and supplemented with 1 mM dithiothreitol, and 
the proteolytic inhibitors 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml 
leupeptin, 10 µM pepstatin A, 2 µM benzamide, 5 µg/ml aprotinin, 50 µg/ml trypsin 
inhibitor, and 1 µg/ml O-phenanthroline. Homogenisation was performed using 10 passes of 
the loose-fitting pestle, and 3 passes of the tight-fitting pestle, of a 40 ml Dounce 
homogeniser (Kontes, DWK Life Sciences (Kimble)).  
2.3. Preparation of subcellular fractions 
 The preparation of subcellular fractions was based on procedures previously developed 
by Lievrement et al. and Prpic et al. [28, 29]. The liver homogenate was centrifuged at 1,500 
g for 10 min. This yielded a low speed pellet, which contains microsomes derived from the 
nuclear membrane and the PM, and a supernatant, which contains mitochondria, microsomes 
derived from the rough and smooth ER, other organelles, and cytosolic proteins [23, 28]. The 
pellet was resuspended in 2 ml of 250 mM sucrose, 25 mM HEPES-KOH, adjusted to pH 
to7.4, containing the proteolytic inhibitors listed above (Wash Medium) to give a final 
volume of about 12 ml. Two different subcellular fractionation strategies, designated the 
“Microsomal and Plasma Membrane Fractionation” strategy and the “Mitochondria, 
Microsomal and Cytosolic Fractionation” strategy, were then employed. In the first (the 
Microsomal and Plasma Membrane Fractionation), the re-suspended low speed pellet was 
used to prepare a PM fraction using Percoll gradient centrifugation as described by Prpić et 
al. [29]. The PM fraction was finally suspended in about 1 ml of 250 mM sucrose, 50 mM 












supernatant was centrifuged at 8,000 g for 20 min. The resulting pellet (the mitochondrial 
fraction) was discarded. The supernatant was centrifuged at 35,000 g for 30 min to yield a 
pellet of heavy microsomes and a supernatant containing light microsomes. The 35,000 g 
supernatant was then centrifuged at 100,000 g for 60 min to yield a pellet of light microsomes 
and a cytosolic fraction which was discarded. The heavy and light microsomal pellets were 
each resuspended by adding 6 ml Wash Medium. In the second subcellular fractionation 
strategy (the Mitochondria, Microsomal and Cytosolic Fractionation), the low speed pellet 
was retained for analysis (designated “low speed pellet”) while the low speed supernatant 
was used to prepare a mitochondrial fraction, heavy and light microsomal fractions, and a 
cytosolic fraction. The low speed (1,500 g) supernatant was centrifuged at 8,000 g for 20 
min. The resulting pellet (the mitochondrial fraction) was resuspended in 6 ml of Wash 
Medium. The supernatant was centrifuged at 35,000 g for 30 min to yield a pellet of heavy 
microsomes and a supernatant, containing light microsomes. The 35,000 g supernatant was 
then centrifuged at 100,000 g for 60 min to yield a pellet of light microsomes and the 
cytosolic fraction. The heavy and light microsomal pellets were each resuspended by adding 
6 ml Wash Medium. The concentration of protein in the liver homogenate and in each 
subcellular fraction was determined by the EZQ method [30],  as described previously [18, 
27]. 
2.4 Treatment of livers with phenylephrine  
 Rats were anesthetized as described above and laparotomy performed to expose the 
inferior vena cava and the liver. Phenylephrine (1 mM stock solution in 0.9% (w/v) NaCl) 
was injected into the inferior vena cava to give an estimated initial blood concentration of 15 
M phenylephrine, based on a  blood volume of 7.5 ml per 100 g body weight [31]. After 20 












and homogenised as described above. During the administration of phenylephrine, the 
breathing and heart rate and degree of secretion from the mouth were monitored in order to 
confirm that phenylephrine induced the expected physiological responses [32]. Blood glucose 
concentrations were measured spectrophotometrically by the glucose oxidase method, using 
an assay kit Sigma (GAGO-20), according to the manufacturer’s instructions.  
2.5. Culture of H4IIE rat liver cells and transfection with siRNA for knockdown of 
peroxiredoxin-4 
The source of H4IIE rat liver cells and conditions of cell culture were as described 
previously [18, 20, 33]. H4IIE cells attached to coverslips were co-transfected with Silencer 
® Select Pre-Designed siRNA (Life Technologies™) targeting rat peroxiredoxin-4 (Catalog 
#: 4390771, Serial: s136933 and s136935) using Lipofectamine® RNAiMAX transfection 
reagent (Life Technologies™), according to the manufacturer’s instructions. As a negative 
control, cells were transfected with Silencer® Select Negative Control (Catalogue 
#: 439084, (Life Technologies™).  
2.6. Western blots 
Western bots were performed as described previously [18, 27]. Samples of subcellular 
fractions were mixed with 50 mM Tris-HCl, pH 6.6, containing 2% (w/v) SDS, 0.1% (w/v) 
bromophenol blue, 10% (v/v) glycerol and 100 mM dithiothreitol (Sample Loading Buffer), 
and heated at 87°C for 10 min. PVDF membranes were blocked with skim milk (5% w/v) 
dissolved in Tris buffer solution containing Tween20 (0.1%) (Blocking Buffer) for 1h at room 
temperature. Secondary antibodies conjugated with horse radish peroxidase (HRP) were used 
to visualise protein bands on the PVDF membrane. All secondary antibodies were diluted in 
Blocking Buffer. Protein bands were visualised using enhanced chemiluminescence detection 












Imager. Image resolution was set to a standard setting of 1536 x1024 pixels and the time of 
exposure was 10 min. The same resolution and exposure time were used in all experiments in 
order to allow quantitative comparison of the results. Band intensity was quantified using 
MultiGauge software (FujiFilm). Local background was subtracted, and the resulting value 
was normalised by the amount of protein loaded onto the gel.  
 The origins and dilutions of the primary and secondary antibodies employed, the bands 
detected, and references for the expected size of each band are listed in Table 1. In order to 
quantitate the amount of a given protein in each subcellular fraction, and to compare the relative 
amount of a given protein between different subcellular fractions, the region over which band 
intensity was a linear function of the amount of protein applied to the gel was determined for 
calreticulin, PMCA, STIM1 and Orai1 (Fig. 1 and Supplemental Data Fig. S1). To determine 
the relative amounts of calreticulin, PMCA, STIM1 and Orai1 in each sub-cellular fraction, 
western blots of the protein present in a given subcellular fraction were conducted. The amount 
of protein applied to the gel (normally 10 to 30 ug per lane) was chosen so as to be in the 
middle of the linear range shown in Fig. 1.  The intensity of the protein band was determined 
(working within the linear range shown in Fig. 1) and was expressed as intensity units per mg 
protein or as intensity units per total volume of subcellular fraction. 
2.7. Immunoprecipitation of STIM1 from the heavy microsomal fraction 
The method employed for immunoprecipitation was based on that described 
previously [26]. Heavy microsomes were dissolved in 150 mM NaCl containing 50 mM Tris-
HCl , 5 mM EGTA, 1% (v/v) Nonidet P-40,  0.25% (w/v) sodium deoxycholate , 0.1% (w/v) 
sodium dodecyl sulphate supplemented with the proteolytic inhibitors 0.2 mM PMSF, 10 µM 
pepstatin A, 10 µg/ml leupeptin (Lysis Buffer) to give a final protein concentration of 5 
mg/ml. Samples of this protein extract were  incubated at 4°C overnight with 1 µg anti-












the mixture incubated at 4°C for another 4 h. The immunoprecipitated proteins and Protein 
A/G PLUS-Agarose were collected by centrifugation at 15,000 g for 10 min at 4°C, and 
washed 3 times with Lysis Buffer. Sample Loading Buffer (40 µl) was added to the 
immunoprecipitate, which included Protein A/G PLUS-Agarose, and the mixture heated at 
87°C for 10 min to elute proteins bound to the Protein A/G PLUS-Agarose.  The eluted 
proteins were separated from Protein A/G PLUS-Agarose by centrifugation at 15,000 g for 1 
min, and were analysed by western blot, as described above, using Any kDTM Mini-
PROTEAN® TGX™ Precast Protein Gels (Bio-Rad Laboratories). STIM1 and Prx-4 bands 
on the PDF membrane were detected using anti-STIM1 antibody (Abcam, # 52458) or anti-
Prx-4 antibody (Biosensis, # R-1593-100), respectively. 
2.8. Identification of proteins in STIM1 immunoprecipitates by LC/MS 
 
Proteins present in STIM1 immunoprecipitates, prepared as described above, were 
identified by LC/MS, as described previously [27]. The resulting spectra were analysed using 
the SEQUEST algorithm (Version 1.2) against the rat International Protein Index (IPI) database 
(Version 3.74, 39,708 protein entries).  
2.8. Measurement of intracellular Ca2+ and store-operated Ca2+ entry 
 [Ca2+]cyt was measured in cells attached to glass coverslips at 37°C using Fura-2 and 
fluorescence imaging microscopy, with an image acquisition time of one image every 10 sec, 
as described previously [18, 21, 34]. The fluorescence ratio (F340nm/F380nm) was converted to 
changes in [Ca2+]cyt according to Grynkiewicz, Poenie and Tsien [35]. Amounts of Ca
2+ 
released were determined by measuring the height of the peak of the DBHQ-induced increase 
in [Ca2+]cyt. Initial rates of Ca
2+ entry were measured using a “Ca2+ add-back” protocol, as 













 Unless stated otherwise, results are expressed as means ± SEM. Statistical significance 
(P<0.05) was determined between groups using one-way analysis of variance (ANOVA) 
followed by Newman-Keuls multiple comparison post hoc test or Student’s t-test (two tailed, 
unpaired). 
3. Results 
3.1. STIM1 and Orai1 are enriched in the microsomal fractions of rat liver 
 To determine the distribution of STIM1 and Orai1 in subcellular fractions of rat liver, 
untreated livers and livers pre-treated with phenylephrine and were homogenised, and the 
homogenate initially subjected to centrifugation at 1,500 g for 10 min. This yielded a low 
speed pellet, which contains microsomes derived from the nuclear membrane and the PM and 
a supernatant, which contains mitochondria, microsomes derived from the rough and smooth 
ER, other organelles and cytosolic proteins [23, 28]. Two different subcellular fractionation 
strategies were then employed. In first (the Microsomal and Plasma Membrane 
Fractionation), the low speed pellet was used to prepare a PM fraction using Percoll gradient 
centrifugation. Heavy and light microsomal fractions were prepared from the low speed 
supernatant. In the second (the Mitochondria, Microsomal and Cytosolic Fractionation), the 
low speed pellet was retained for analysis while the low speed supernatant was used to 
prepare a mitochondrial fraction, heavy and light microsomal fractions, and a cytosolic 
fraction. 
 The distribution of the ER marker protein calreticulin [36] and the PM marker protein 
PMCA [37-39] in subcellular fractions derived from untreated livers was determined by 












corresponding to calreticulin and PMCA. The results are shown in Fig. 2 and in 
Supplemental Data Fig.S2). Relative to whole liver, calreticulin was enriched in the heavy 
microsomes, light microsomes, and mitochondria (Fig. 2A-C). The detection of some 
calreticulin in the PM subcellular fraction may be due, in part, to: the presence, in the PM 
subcellular fraction, of some microsomes derived from the ER, and/or to the localisation of 
some calreticulin in the PM itself in intact hepatocytes [40]. PMCA was principally 
enriched in the in the PM fraction (Fig. 2 A, D).  These results provide evidence that the 
fractions designated “heavy microsomes” and “light microsomes” are enriched in 
microsomes derived from the ER, and that the fraction designated “PM” is enriched in 
microsomes derived from the PM. 
 The distribution of STIM1 and Orai1 in subcellular fractions derived from untreated 
livers is shown in Figs. 3 and 4 (expressed as relative units of band intensity per mg protein), 
in Table 2 (expressed as relative units of band intensity per total volume of fraction), and in 
Supplemental Data Figs. S3 and S4. The sizes of the bands detected by the anti-1 STIM1 and 
anti-Orai1 antibodies were 75 and 45 kDa, respectively (Figs. 3 and 4 and Supplemental Data 
Figs. 3 and 4). The size (45 kDa) of the band detected by the anti-Orai1 antibody corresponds 
to the glycosylated form of Orai1[16, 41] and is similar to the size of endogenous Orai1 
observed previously in hepatocytes and liver cells [18] and in other mammalian cell types 
[42, 43]. Relative to whole liver, STIM1 was enriched in the heavy and light microsomal 
fractions, with no detectable enrichment in the PM fraction or in the low speed pellet (Fig. 3). 
Others have previously shown that the low speed pellet contains microsomes derived from 
the PM [29]. About 85% of all the STIM1 was found in the heavy microsomal fraction (Table 
2). Orai1 was enriched in the heavy and light microsomal fractions with little enrichment in 
the PM fraction (Fig. 4). About 50% of all the Orai1 was found in the heavy microsomal 












 On the basis of many previous studies [1, 11, 16], it had been expected that Orai1 
would be principally located in the PM fraction, rather than in microsomal fractions derived 
from the ER. In view of this somewhat unexpected observation, we compared the distribution 
of Orai1 with that of another ion channel protein, the transient receptor potential melastatin 2 
(TRPM2) non-selective cation channel, thought to be principally located in the PM of animal 
cells [34].  TRPM2 is expressed in rat hepatocytes and is functional in the PM [34]. Relative 
to whole liver, TRPM2 was enriched in the low speed pellet (which contains PM vesicles) 
and mitochondria (Fig. 5 A,B). In contrast to Orai1, no enrichment of TRPM2 was observed 
in the heavy or light microsomal fractions. 
 In some cell types, it has been shown that, in addition to its role in forming SOCs in the 
PM, Orai1 is located in acidic intracellular stores, including secretory granules, where it 
mediates Ca2+ release from these granules [44, 45]. Therefore, we also compared the 
distribution of Orai1 in liver subcellular fractions with that of two secretory granule marker 
proteins, secretory pathway Ca2+ ATP-ase 1 and 2 (SPCA1 and SPCA2), using an antibody 
which recognises both of these proteins. While SPCA1 and SPCA2 were difficult to detect in 
western blots, SPCA1 was enriched principally in the cytosolic and light microsomal 
fractions, while SPCA2 was principally enriched in the cytosolic fraction with little 
enrichment in the light or heavy microsomal fractions (Fig. 5C). Comparison of the 
distribution in subcellular fractions of SPCA1 and 2 with that of Orai1 suggests that the 
location of Orai1 in secretory granules is unlikely to account for the large amount of Orai1 
found in the heavy microsomal fraction. 
3.2. Pre-treatment with phenylephrine does not lead to a detectable change in the distribution 












 The results of many experiments employing cells transfected with STIM1 tagged with a 
fluorescent polypeptide such as GFP, have shown that Ca2+ release from the ER causes 
STIM1 to form puncta and increases the amount of STIM1 associated with the PM [1]. To 
determine whether the release of Ca2+ from the ER and the subsequent activation of SOCE 
lead to a detectable change in the distribution of STIM1 and/or Orai1 in liver subcellular 
fractions, livers were pre-treated in vivo with phenylephrine, an -adrenergic agonist which 
activates SOCE in hepatocytes [46]. As shown previously [47], following 20 min exposure to 
phenylephrine, the blood glucose concentration was increased to 28 ± 2 mM compared with 
controls 19 ± 2 mM (means ± SEM, n=3).  (The blood glucose concentration in both control 
and phenylephrine-treated rats was elevated by the ketamine xylazine anaesthesia [48]). 
Phenylephrine pre-treatment did not cause a detectable change in the distribution of STIM1 
or Orai1 (Figs. 3 and 4, and Table 2). 
3.3. Identification of peroxiredoxin-4 as a potential STIM1 binding protein  
 The results described above have shown that, in subcellular fractions of liver, STIM1 is 
predominantly located in the heavy microsomal fraction (derived from the rough ER) with 
some in the light microsomal fraction (derived from the smooth ER). The activation of Orai1 
by STIM1 occurs in the cortical ER [5, 6]. This is devoid of ribosomes and hence, upon 
homogenisation of the whole liver, is likely to generate microsomes which sediment in the 
light microsomal fraction. On the one hand, STIM1 located in heavy microsomes is unlikely 
to be directly involved in the activation of Orai1. On the other hand, it has been shown that 
STIM1 can interact with a number of other proteins as well as with Orai1. Many of these are 
located in the rough ER [8]. Therefore, we searched for STIM1 binding proteins in the heavy 
microsomal fraction. The strategy employed was to immunoprecipitate STIM1 using an anti-













To confirm that STIM1 could be immunoprecipitated from proteins extracted from 
the heavy microsomal fraction, western blot was used to determine whether STIM1 was 
present in the immunoprecipitate obtained using an anti-STIM1 antibody. The results indicate 
that STIM1 is enriched in the immunoprecipitate (Fig. 6A). Proteins present in 
immunoprecipitates obtained using the anti-STIM1 antibody were hydrolysed and the 
peptides analysed by LC/MS. Table 3 lists fourteen proteins which were identified in the ant-
STIM1 immunoprecipitate but were not present in the IgG control. These proteins include 
STIM1, keratin, nuclear binding proteins, peroxiredoxin-4 (Prx-4), as well as several other 
proteins. The presence of STIM1 confirms that the immunoprecipitation was successful. 
Keratin and ProteinKrt16 are likely to be skin contaminants [49] and some nuclear binding 
proteins are known to bind non-specifically to agarose beads employed for the 
immunoprecipitation [50]. Prx-4 was of interest since several studies have shown that SOCE, 
and STIM1 and Orai1, can be modified by ROS [3, 4].  Moreover, it is known that Prx-4 is 
located in the lumen of the ER where, together with a protein disulphide isomerase and ER 
oxidoreductase 1, it is thought to catalyse the conversion of H2O2 to H2O [51-54]. 
The potential interaction of Prx-4 with STIM1 was investigated further by 
determining the distribution of Prx-4 in subcellular fractions of liver using western blot. Two 
bands of Prx-4 were detected, corresponding to the Prx-4 monomer (25 kDa) and dimer (50 
kDa) [53, 55] (Fig. 6B). Prx-4 was principally enriched in the heavy microsomal fraction 
with some enrichment in the light microsomal and mitochondrial fractions (Fig. 6B,C). 
Immunoprecipitation of STIM1 and analysis of the immunoprecipitate by western blot using 
an anti-Prx-4 antibody indicated that Prx-4 is enriched in the anti-STIM1 immunoprecipitate 












To investigate the possible role of Prx-4 in regulating the activity of STIM1, 
experiments were conducted with cultured H4IIE rat liver cells. Prx-4 was knocked down 
using siRNA, and the effects of decreased Prx-4 expression on SOCE, measured in the 
presence and absence of H2O2, were then assessed. Incubation of H4IIE cells with siRNA 
targeted against Prx-4 decreased the expression of Prx-4 by 26 ± 4 % (mean ± SEM, n=3) 
(Fig. 6E). In cells incubated in the absence of H2O2, knockdown of Prx-4 did not alter either 
Ca2+ release from the ER, initiated by 2,5-di-(tert-butyl)-1,4-benzohydro-quinone (DBHQ), 
an inhibitor of the ER (Ca2+ + Mg2+) ATP-ase [18], or Ca2+ entry, initiated by the subsequent 
addition of extracellular Ca2+ (Fig. 7A,C, and E,F). Addition of H2O2 to cells pre-treated with 
negative control siRNA did not inhibit Ca2+ release or Ca2+ entry (Fig. 7A,B, and E,F). 
However, addition of H2O2 to cells pre-treated with siRNA targeted against Prx-4 inhibited 
Ca2+ entry but did not alter Ca2+ release, relative to that in negative control cells (Fig. 7B,D 
and E,F). In an alternative approach, H4IIE liver cells were treated with Conoidin A, an 
inhibitor of Prx-4 and of some other peroxiredoxin enzymes [56-58]. The effects of Conoidin 
A in the presence and absence of H2O2 were similar to those observed in cells pre-treated 
with siRNA targeted against Prx-4 (Fig. 8). 
4. Discussion 
 The aim of this study was to investigate the intracellular distribution of endogenous 
Orai1 and STIM1in hepatocytes, and to look for novel intracellular STIM1 binding proteins. 
The strategy employed was to subject the liver to subcellular fractionation then determine the 
amounts of Orai1 and STIM1 in the major subcellular fractions. The main findings can be 
summarised as follows. The majority of Orai1 was found in the heavy (44%) and light (27%) 
microsomal fractions, with only a small proportion (0.03%)in the PM fraction. The majority 












microsomal fraction and a small component (0.09%) in the PM fraction. Immunoprecipitation 
and LC/MS identified Prx-4 as a potential STIM1 binding protein. Knockdown of Prx-4 
using siRNA, or inhibition of Prx-4 using conoidin A, did not affect SOCE measured in the 
absence of H2O2, a generator of ROS, but did result in the inhibition of SOCE by H2O2. 
 The conditions of liver homogenisation and differential centrifugation employed in the 
present study to isolate the heavy and light microsomal and PM fractions were based on those 
employed previously by others for subcellular fractionation of the liver [23, 28].  The 
observed distribution of calreticulin and PMCA, markers for the ER and PM, respectively, 
indicates that there are relatively little PM-derived vesicles in the microsomal fractions while 
there are some ER-derived vesicles in PM fraction. Hepatocytes comprise about 80% of the 
cells in the liver [22]. Therefore, it is likely that results for the distribution of STIM1 and 
Orai1in subcellular fractionations derived from whole liver tissue principally reflect the 
distribution of Orai1 and STIM1 in hepatocytes, rather than the distribution of these proteins 
in other cell types present in the liver. Since the PM marker, PMCA, was predominantly 
located in the PM fraction with little in the microsomal fractions, it is unlikely that the 
presence of Orai1 in the microsomal fractions is due to contamination of those fractions by 
large amounts of microsomes derived from the PM. 
The observations that Prx-4 was detected in the proteins extracted from heavy 
microsomes following immunoprecipitation with STIM1, that STIM1 was detected when 
proteins from the heavy microsomal fraction were subjected to immunoprecipitation using an 
anti-Prx-4 antibody, and that the enrichment of Prx-4 in the heavy microsomal fraction 
corresponds to the enrichment of STIM1 in this fraction provide evidence for an association 
of STIM1 and Prx-4 in the rough ER. 
Previous studies have shown that Prx-4 is located in the lumen of the ER where, 












catalyse the conversion of H2O2 to H2O ([51-54].  This pathway, which is responsible for the 
oxidation of sulphydryl groups on cysteine residues of newly-synthesised proteins to 
disulphide bonds, is one of the steps in the folding of newly-synthesised proteins [51]. Prx-4 
also removes H2O2, generated by other oxidase reactions, from the ER lumen [51]. The 
correct folding of newly-synthesised STIM1 polypeptides may involve the oxidation of two 
cysteine residues, Cys56 and Cys49 [3]. Several protein disulphide isomerases are involved 
in protein folding in the ER [51, 59, 60]. One of these isomerases, ERp57, may play an 
additional role in regulating the activity of STIM1. Thus, it has been shown that the binding 
of ERp57 to STIM1 inhibits the activation of Orai1 and hence inhibits SOCE [3, 59, 61].  It 
has also been shown that ROS or H2O2 can modify cysteine thiol  residues on STIM1 and 
Orai1 leading to activation of STIM1 and inhibition of  Orai1, although interpretation of 
these results is somewhat complicated (reviewed in [1, 3, 4]). 
The present observations that, in liver cells, knockdown of Prx-4 or the inhibition of 
Prx-4 using Conoidin A [56-58], render SOCE susceptible to inhibition by H2O2, a generator 
of ROS [34],  suggests that the functional significance of the interaction of Prx-4 with STIM1 
may be to allow Prx-4 to efficiently remove ROS from the vicinity of STIM1, and/or to 
permit the correct folding of newly-synthesised STIM1. These hypothesised roles of Prx-4 in 
regulating the activity and/or folding of STIM1 are shown schematically in Fig. 9. While the 
experiments involving knockdown of Prx-4 or inhibition of Prx-4 were conducted using 
H4IIE rat liver cells, previous studies have provided evidence that the properties of SOCs in 
H4IIE cells are similar to those in rat hepatocytes [20]. 
 
The observation that, in liver, the majority of endogenous Orai1 was found in 
microsomes derived from the smooth and rough ER rather than in the PM was somewhat 












results of many previous experiments conducted with numerous cell types in which ectopic 
Orai1 tagged with a fluorescent protein such as GFP has been overexpressed have shown that 
Orai1 is principally located at or near the PM [1, 11, 12, 16]. However, the results of several 
other studies provide evidence for the internalisation of Orai1 to endosomes, cycling and 
trafficking of Orai1 between the PM and intracellular organelles, and the location of Orai in 
acidic organelles including secretory granules [43-45, 62-66]. It is also interesting to note that 
the distribution of Orai1 amongst the liver subcellular fractions is quite different from that of 
TRPM2. It is thought that TRPM2 principally functions at the PM, but may also be present in 
lysosomes, and is also likely to be trafficked to and from the PM [67, 68]. 
One explanation for the apparent difference between the present results obtained from 
studying endogenous Orai1 using subcellular fractionation and those obtained from studies of 
overexpressed ectopic Orai1 in cultured immortalised cells is that, in hepatocytes, Orai1 is 
located in regions of the rough ER which are close to the PM but which upon homogenisation 
form heavy microsomes which sediment with the heavy microsomal fraction. A second 
explanation may be that Orai1 expressed ectopically is trafficked to some intracellular 
locations which are different from those for endogenous Orai1. The function of Orai1 located 
in the smooth and rough ER may be to provide a reservoir of Orai1 for insertion into the PM 
and/or may represent newly-synthesised Orai1 being trafficked to the PM [43, 65]. Another 
consideration is that, in the present study, the distribution of Orai1 and STIM1 has been 
studied in subcellular fractions derived from spatially polarised hepatocytes in situ, whereas, 
as mentioned above, many other studies of the intracellular localisation of these proteins have 
been conducted with cells, often immortalised, in culture. 
The observation that the distribution of the secretory granule markers SPCA1 and 
SPCA2 did not match that of Orai1, suggests that localisation of Orai1 in these organelles 












fractions. However, this does not preclude the presence of some functional Orai1 in secretory 
granules in hepatocytes, as found in PC12 cells [44]. 
The majority of STIM1 was found to be located in heavy microsomes derived from 
the rough ER with little in the PM fraction. This distribution is broadly consistent with the 
results of previous studies on the distribution of endogenous STIM1 in K562 cells and in 
HEK 293 cells [69, 70]. STIM1 polypeptides involved in the activation of Orai1 at PM-ER 
junctions would be expected to reside and function in the smooth ER at the periphery of the 
cell adjacent to the PM [1, 13, 15].  Several previous studies have provided evidence that 
bulky ribosomes attached to the rough ER would prevent the ER from coming sufficiently 
close to the PM in a PM-ER junction so that STIM1 polypeptides can interact with Orai1 
polypeptides [5, 6]. The amount of cortical ER involved in PM-ER junctions is likely to be a 
very small proportion of the total in the ER. This raises the question of the likely function of 
STIM1 located in the rough ER. This presumably does not participate directly in the 
activation of Orai1. However, STIM1 located in the rough ER may provide a reservoir of 
STIM1 for supply to the cortical ER, may regulate other functions of the ER independent of 
interaction with Orai1, and may be involved in the regulation of microtubule formation and 
remodelling of the ER [8-10, 71, 72]. 
Treatment with phenylephrine to release Ca2+ from intracellular stores and activate 
SOCE did not cause a detectable change in the distribution of Orai1 and STIM1 between 
subcellular fractions.  There is some evidence to indicate that the activation of Orai1, and 
hence SOCE, by STIM1 may involve an increase in the amounts of Orai1 and/or STIM1 in 
the PM (reviewed by Prakriya and Lewis [1]). However, such a redistribution of STIM1 and 
Orai1 is likely to involve a very small fraction of the total amounts of these proteins present 
in the hepatocyte and would not be detected in the present study of subcellular fractions. In 












is associated with the trafficking of significant amounts of Orai1 to the PM [43, 73]. It is 
possible that in hepatocytes in situ, pre-treatment with thapsigargin leads to a much larger 
release of ER Ca2+ than that induced by phenylephrine, the hormone analogue employed in 
the present study. This may, in turn, cause a larger increase in Orai1 in the PM fraction, 
which might have been detectable using the subcellar fractionation approach employed in this 
study. Indeed, many other conditions, such as steatosis or drug-induced liver toxicity, are 
known to cause ER stress and an increase in ROS in hepatocytes [18, 34, 74].  These may 
also cause a larger release of ER Ca2+ than that initiated by phenylephrine and may also cause 
an increase the amount of Orai1 in the PM fraction which would be detectable by the 
subcellular fractionation approach. 
 
The association of Prx-4 with STIM1 may also affect the activity and intracellular 
distribution of Orai1. A relationship between the concentration of ROS, Orai1, and SOCE has 
been reported in mast cells [75]. In the present study, the experiments to investigate the role 
of Prx-4 in the regulation of SOCE were conducted using H4IIE rat liver cells in culture. 
Under these cell culture conditions, some of the cells are proliferating, the concentration of 
ROS may be elevated, and ER Ca2+ may be partly depleted. Studies of the intracellular 
distribution of Orai1 and STIM1 were conducted using homogenates of rat liver where the 
majority of hepatocytes are quiescent and the concentration of ROS within hepatocytes is 
likely low. It is possible that in H4IIE cells in culture more Orai1 may be located at the PM 
than in quiescent hepatocytes, leading to greater Ca2+ entry via SOCE. Further studies to 
compare the trafficking of Orai1 to the PM and the amount of Orai1 in the PM in both 
quiescent hepatocytes in situ and in proliferating H4IIE cells in culture under conditions of 












It is concluded that, in hepatocytes in situ, a considerable proportion of endogenous 
Orai1 and STIM1 is located in the ER. Orai1 present in the ER may be close to the PM where 
it may provide a reservoir of Orai1 for insertion into the PM as part of the cycling of Orai1 
between the PM and ER in the regulation of SOCE.  STIM1 present in the ER may be 
involved in processes independent of SOCE, such as the regulation of microtubules, and may 
also represent STIM1 being trafficked to the PM. In addition, STIM1 interacts with Prx-4, 




This study was supported by grants from the Australian Research Council 
(DP140100259), National Health and Medical Research Council (519115), Flinders 
University, and the Flinders Medical Centre Foundation.  
Conflict of Interest Statement 
 
We wish to confirm that there are no known conflicts of interest associated with this publication and 
there has been no significant financial support for this work that could have influenced its outcome.  
 
Acknowledgements 
 Advice provided by Dr. Yabin Zhou and Nusha Chegeni, Flinders University, 
Adelaide; and Dr Sarah Ho, Hong Kong University of Science and Technology, Hong Kong, 


















[1] M. Prakriya, R.S. Lewis, Store-Operated Calcium Channels, Physiological reviews, 95 
(2015) 1383-1436. 
[2] D.M. Cooper, Store-operated Ca(2)(+)-entry and adenylyl cyclase, Cell Calcium, 58 
(2015) 368-375. 
[3] P. Nunes, N. Demaurex, Redox regulation of store-operated Ca2+ entry, Antioxidants & 
redox signaling, 21 (2014) 915-932. 
[4] R. Bhardwaj, M.A. Hediger, N. Demaurex, Redox modulation of STIM-ORAI signaling, 
Cell Calcium, 60 (2016) 142-152. 
[5] G. Lur, L.P. Haynes, I.A. Prior, O.V. Gerasimenko, S. Feske, O.H. Petersen, R.D. 
Burgoyne, A.V. Tepikin, Ribosome-free terminals of rough ER allow formation of STIM1 
puncta and segregation of STIM1 from IP(3) receptors, Curr Biol, 19 (2009) 1648-1653. 
[6] L. Orci, M. Ravazzola, M. Le Coadic, W.W. Shen, N. Demaurex, P. Cosson, STIM1-
induced precortical and cortical subdomains of the endoplasmic reticulum, Proceedings of the 
National Academy of Sciences of the United States of America, 106 (2009) 19358-19362. 
[7] N.R. Scrimgeour, D.P. Wilson, G.J. Barritt, G.Y. Rychkov, Structural and stoichiometric 
determinants of Ca2+ release-activated Ca2+ (CRAC) channel Ca2+-dependent inactivation, 
Biochimica et biophysica acta, 1838 (2014) 1281-1287. 
[8] R. Hooper, E. Samakai, J. Kedra, J. Soboloff, Multifaceted roles of STIM proteins, 
Pflugers Archiv : European journal of physiology, 465 (2013) 1383-1396. 
[9] W.W. Shen, M. Frieden, N. Demaurex, Remodelling of the endoplasmic reticulum during 
store-operated calcium entry, Biol Cell, 103 (2011) 365-380. 
[10] J.T. Smyth, W.I. DeHaven, G.S. Bird, J.W. Putney, Jr., Role of the microtubule 
cytoskeleton in the function of the store-operated Ca2+ channel activator STIM1, Journal of 
cell science, 120 (2007) 3762-3771. 
[11] V.A. Barr, K.M. Bernot, S. Srikanth, Y. Gwack, L. Balagopalan, C.K. Regan, D.J. 
Helman, C.L. Sommers, M. Oh-Hora, A. Rao, L.E. Samelson, Dynamic movement of the 
calcium sensor STIM1 and the calcium channel Orai1 in activated T-cells: puncta and distal 
caps, Mol Biol Cell, 19 (2008) 2802-2817. 
[12] M. Chvanov, C.M. Walsh, L.P. Haynes, S.G. Voronina, G. Lur, O.V. Gerasimenko, R. 
Barraclough, P.S. Rudland, O.H. Petersen, R.D. Burgoyne, A.V. Tepikin, ATP depletion 
induces translocation of STIM1 to puncta and formation of STIM1-ORAI1 clusters: 
translocation and re-translocation of STIM1 does not require ATP, Pflugers Archiv : 
European journal of physiology, 457 (2008) 505-517. 
[13] J.T. Smyth, W.I. Dehaven, G.S. Bird, J.W.J. Putney, Ca2+-store-dependent and -
independent reversal of Stim1 localization and function, Journal of cell science, 121 (2008) 
762-772. 
[14] R.M. Luik, M.M. Wu, J. Buchanan, R.S. Lewis, The elementary unit of store-operated 
Ca2+ entry: local activation of CRAC channels by STIM1 at ER-plasma membrane 
junctions, Journal of Cell Biology, 174 (2006) 815-825. 
[15] M.M. Wu, J. Buchanan, R.M. Luik, R.S. Lewis, Ca2+ store depletion causes STIM1 to 
accumulate in ER regions closely associated with the plasma membrane, Journal of Cell 












[16] Y. Gwack, S. Srikanth, S. Feske, F. Cruz-Guilloty, M. Oh-hora, D.S. Neems, P.G. 
Hogan, A. Rao, Biochemical and functional characterization of Orai proteins, J Biol Chem, 
282 (2007) 16232-16243. 
[17] G. Rychkov, H.M. Brereton, M.L. Harland, G.J. Barritt, Plasma membrane Ca2+ 
release-activated Ca2+ channels with a high selectivity for Ca2+ identified by patch-clamp 
recording in rat liver cells, Hepatology, 33 (2001) 938-947. 
[18] C.H. Wilson, E.S. Ali, N. Scrimgeour, A.M. Martin, J. Hua, G.A. Tallis, G.Y. Rychkov, 
G.J. Barritt, Steatosis inhibits liver cell store-operated Ca(2)(+) entry and reduces ER 
Ca(2)(+) through a protein kinase C-dependent mechanism, Biochem J, 466 (2015) 379-390. 
[19] G.Y. Rychkov, T. Litjens, M.L. Roberts, G.J. Barritt, ATP and vasopressin activate a 
single type of store-operated Ca2+ channel, identified by patch-clamp recording, in rat 
hepatocytes, Cell Calcium, 37 (2005) 183-191. 
[20] E.C. Aromataris, J. Castro, G. Rychkov, G.J. Barritt, Store-operated Ca2+ channels and 
Stromal Interaction Molecule 1 (STIM1) are targets for the actions of bile acids on liver cells, 
Biochimica et Biophysica Acta - Molecular Cell Research, 1783 (2008) 874-885. 
[21] J. Castro, E.C. Aromataris, G.Y. Rychkov, G.J. Barritt, A small component of the 
endoplasmic reticulum is required for store-operated Ca2+ channel activation in liver cells: 
evidence from studies using TRPV1 and taurodeoxycholic acid, Biochem J, 418 (2009) 553-
566. 
[22] B. Young, J.W. Heath, Liver and Pancreas,  Wheater's Functional Histology, Churchill 
Livingstone, Edinburgh, 2000, pp. 274-275. 
[23] A. Amar-Costesec, H. Beaufay, M. Wibo, D. Thines-Sempoux, E. Feytmans, M. Robbi, 
J. Berthet, Analytical study of microsomes and isolated subcellular membranes from rat liver. 
II. Preparation and composition of the microsomal fraction, The Journal of cell biology, 61 
(1974) 201-212. 
[24] J.H. Cox, S. Hussell, H. Sondergaard, K. Roepstorff, J.V. Bui, J.R. Deer, J. Zhang, Z.G. 
Li, K. Lamberth, P.H. Kvist, S. Padkjaer, C. Haase, S. Zahn, V.H. Odegard, Antibody-
mediated targeting of the Orai1 calcium channel inhibits T cell function, PLoS One, 8 (2013) 
e82944. 
[25] H.L. Ong, J. Chen, T. Chataway, H. Brereton, L. Zhang, T. Downs, L. Tsiokas, G. 
Barritt, Specific detection of the endogenous transient receptor potential (TRP)-1 protein in 
liver and airway smooth muscle cells using immunoprecipitation and Western-blot analysis,  
Biochemical Journal 364 (2002) 641-648. 
[26] T. Litjens, T. Nguyen, J. Castro, E.C. Aromataris, L. Jones, G.J. Barritt, G.Y. Rychkov, 
Phospholipase C-gamma1 is required for the activation of store-operated Ca2+ channels in 
liver cells, Biochem J, 405 (2007) 269-276. 
[27] C. Wilson, S. Zeile, T. Chataway, V.B. Nieuwenhuijs, R.T.A. Padbury, G.J. Barritt, 
Increased expression of peroxiredoxin 1 and a novel lipid metabolising enzyme in the early 
phase of liver ischemia reperfusion injury, Proteomics, (2011). 
[28] J.-P. Lievremont, A.-M. Hill, M. Hilly, J.-P. Mauger, The inositol 1,4,5-trisphosphate 
receptor is localised on specialised sub-regions of the endoplasmic reticulum in rat liver,  
Biochem J 300 (1994) 419-427. 
[29] V. Prpic, K.C. Green, P.F. Blackmore, J.H. Exton, Vasopressin-, angiotensin II-, and 
alpha 1-adrenergic-induced inhibition of Ca2+ transport by rat liver plasma membrane 
vesicles, J Biol Chem, 259 (1984) 1382-1385. 
[30] B.J. Agnew, D. Murray, W.F. Patton, A rapid solid-phase fluorescence-based protein 
assay for quantitation of protein electrophoresis samples containing detergents, chaotropes, 












[31] N.B. Argent, J. Liles, D. Rodham, C.B. Clayton, R. Wilkinson, P.H. Baylis, A new 
method for measuring the blood volume of the rat using 113mIndium as a tracer, Lab Anim, 
28 (1994) 172-175. 
[32] R. Naderi, A. Imani, M. Faghihi, M. Moghimian, Phenylephrine induces early and late 
cardioprotection through mitochondrial permeability transition pore in the isolated rat heart, J 
Surg Res, 164 (2010) e37-42. 
[33] E.C. Aromataris, M.L. Roberts, G.J. Barritt, G.Y. Rychkov, Glucagon activates Ca2+ 
and Cl- channels in rat hepatocytes, J Physiol (Lond), 573 (2006) 611-625. 
[34] E. Kheradpezhouh, L. Ma, A. Morphett, G.J. Barritt, G.Y. Rychkov, TRPM2 channels 
mediate acetaminophen-induced liver damage, Proceedings of the National Academy of 
Sciences of the United States of America, 111 (2014) 3176-3181. 
[35] G. Grynkiewicz, M. Poenie, R.Y. Tsien, A new generation of Ca2+ indicators with 
greatly improved fluorescence properties, J Biol Chem, 260 (1985) 3440-3450. 
[36] M.J. Smith, G.L. Koch, Multiple zones in the sequence of calreticulin (CRP55, 
calregulin, HACBP), a major calcium binding ER/SR protein, EMBO J, 8 (1989) 3581-3586. 
[37] H. Hilfiker, D. Guerini, E. Carafoli, Cloning and expression of isoform 2 of the human 
plasma membrane Ca2+ ATPase. Functional properties of the enzyme and its splicing 
products, J Biol Chem, 269 (1994) 26178-26183. 
[38] F. Kessler, F. Bennardini, O. Bachs, J. Serratosa, P. James, A.J. Caride, P. Gazzotti, J.T. 
Penniston, E. Carafoli, Partial purification and characterization of the Ca2(+)-pumping 
ATPase of the liver plasma membrane, J Biol Chem, 265 (1990) 16012-16019. 
[39] N. Tolosa de Talamoni, C.A. Smith, R.H. Wasserman, C. Beltramino, C.S. Fullmer, J.T. 
Penniston, Immunocytochemical localization of the plasma membrane calcium pump, 
calbindin-D28k, and parvalbumin in Purkinje cells of avian and mammalian cerebellum, 
Proceedings of the National Academy of Sciences of the United States of America, 90 (1993) 
11949-11953. 
[40] I. Garcia-Arcos, Y. Rueda, P. Gonzalez-Kother, L. Palacios, B. Ochoa, O. Fresnedo, 
Association of SND1 protein to low density lipid droplets in liver steatosis, J Physiol 
Biochem, 66 (2010) 73-83. 
[41] R. Guzman, E.G. Valente, J. Pretorius, E. Pacheco, M. Qi, B.D. Bennett, D.H. Fong, 
F.F. Lin, V. Bi, H.J. McBride, Expression of ORAII, a plasma membrane resident subunit of 
the CRAC channel, in rodent and non-rodent species, J Histochem Cytochem, 62 (2014) 864-
878. 
[42] H. Balghi, R. Robert, B. Rappaz, X. Zhang, A. Wohlhuter-Haddad, A. Evagelidis, Y. 
Luo, J. Goepp, P. Ferraro, P. Romeo, M. Trebak, P.W. Wiseman, D.Y. Thomas, J.W. 
Hanrahan, Enhanced Ca2+ entry due to Orai1 plasma membrane insertion increases IL-8 
secretion by cystic fibrosis airways, FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology, 25 (2011) 4274-4291. 
[43] G.E. Woodard, G.M. Salido, J.A. Rosado, Enhanced exocytotic-like insertion of Orai1 
into the plasma membrane upon intracellular Ca2+ store depletion, American journal of 
physiology. Cell physiology, 294 (2008) C1323-1331. 
[44] E.J. Dickson, J.G. Duman, M.W. Moody, L. Chen, B. Hille, Orai-STIM-mediated Ca2+ 
release from secretory granules revealed by a targeted Ca2+ and pH probe, Proceedings of 
the National Academy of Sciences of the United States of America, 109 (2012) E3539-3548. 
[45] H. Zbidi, I. Jardin, G.E. Woodard, J.J. Lopez, A. Berna-Erro, G.M. Salido, J.A. Rosado, 
STIM1 and STIM2 are located in the acidic Ca2+ stores and associates with Orai1 upon 
depletion of the acidic stores in human platelets, J Biol Chem, 286 (2011) 12257-12270. 
[46] P.H. Reinhart, W.M. Taylor, F.L. Bygrave, Calcium ion fluxes induced by the action of 












[47] D.A. Hems, P.D. Whitton, G.Y. Ma, Metabolic actions of vasopressin, glucagon and 
adrenalin in the intact rat, Biochimica et biophysica acta, 411 (1975) 155-164. 
[48] J.K. Saha, J. Xia, J.M. Grondin, S.K. Engle, J.A. Jakubowski, Acute hyperglycemia 
induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical 
models, Exp Biol Med (Maywood), 230 (2005) 777-784. 
[49] K. Hodge, S.T. Have, L. Hutton, A.I. Lamond, Cleaning up the masses: exclusion lists to 
reduce contamination with HPLC-MS/MS, J Proteomics, 88 (2013) 92-103. 
[50] L. Trinkle-Mulcahy, S. Boulon, Y.W. Lam, R. Urcia, F.M. Boisvert, F. Vandermoere, 
N.A. Morrice, S. Swift, U. Rothbauer, H. Leonhardt, A. Lamond, Identifying specific protein 
interaction partners using quantitative mass spectrometry and bead proteomes, The Journal of 
cell biology, 183 (2008) 223-239. 
[51] S.G. Rhee, H.A. Woo, I.S. Kil, S.H. Bae, Peroxiredoxin functions as a peroxidase and a 
regulator and sensor of local peroxides, J Biol Chem, 287 (2012) 4403-4410. 
[52] E. Zito, PRDX4, an endoplasmic reticulum-localized peroxiredoxin at the crossroads 
between enzymatic oxidative protein folding and nonenzymatic protein oxidation, 
Antioxidants & redox signaling, 18 (2013) 1666-1674. 
[53] E. Zito, E.P. Melo, Y. Yang, A. Wahlander, T.A. Neubert, D. Ron, Oxidative protein 
folding by an endoplasmic reticulum-localized peroxiredoxin, Mol Cell, 40 (2010) 787-797. 
[54] T.J. Tavender, J.J. Springate, N.J. Bulleid, Recycling of peroxiredoxin IV provides a 
novel pathway for disulphide formation in the endoplasmic reticulum, EMBO J, 29 (2010) 
4185-4197. 
[55] Y. Sato, R. Kojima, M. Okumura, M. Hagiwara, S. Masui, K. Maegawa, M. Saiki, T. 
Horibe, M. Suzuki, K. Inaba, Synergistic cooperation of PDI family members in 
peroxiredoxin 4-driven oxidative protein folding, Sci Rep, 3 (2013) 2456. 
[56] J.D. Haraldsen, G. Liu, C.H. Botting, J.G. Walton, J. Storm, T.J. Phalen, L.Y. Kwok, D. 
Soldati-Favre, N.H. Heintz, S. Muller, N.J. Westwood, G.E. Ward, Identification of Conoidin 
a as a Covalent Inhibitor of Peroxiredoxin Ii, Org Biomol Chem, 7 (2009) 3040-3048. 
[57] G. Liu, C.H. Botting, K.M. Evans, J.A. Walton, G. Xu, A.M. Slawin, N.J. Westwood, 
Optimisation of conoidin A, a peroxiredoxin inhibitor, ChemMedChem, 5 (2010) 41-45. 
[58] J.B. Nguyen, C.D. Pool, C.Y. Wong, R.S. Treger, D.L. Williams, M. Cappello, W.A. 
Lea, A. Simeonov, J.J. Vermeire, Y. Modis, Peroxiredoxin-1 from the human hookworm 
Ancylostoma ceylanicum forms a stable oxidized decamer and is covalently inhibited by 
conoidin A, Chem Biol, 20 (2013) 991-1001. 
[59] A. Hettinghouse, R. Liu, C.J. Liu, Multifunctional molecule ERp57: From cancer to 
neurodegenerative diseases, Pharmacol Ther, 181 (2018) 34-48. 
[60] C.E. Jessop, R.H. Watkins, J.J. Simmons, M. Tasab, N.J. Bulleid, Protein disulphide 
isomerase family members show distinct substrate specificity: P5 is targeted to BiP client 
proteins, Journal of cell science, 122 (2009) 4287-4295. 
[61] D. Prins, J. Groenendyk, N. Touret, M. Michalak, Modulation of STIM1 and 
capacitative Ca2+ entry by the endoplasmic reticulum luminal oxidoreductase ERp57, 
EMBO Rep, 12 (2011) 1182-1188. 
[62] A. Bohorquez-Hernandez, E. Gratton, J. Pacheco, A. Asanov, L. Vaca, Cholesterol 
modulates the cellular localization of Orai1 channels and its disposition among membrane 
domains, Biochimica et biophysica acta, 1862 (2017) 1481-1490. 
[63] J.T. Smyth, J.W. Putney, Regulation of store-operated calcium entry during cell division, 
Biochem Soc Trans, 40 (2012) 119-123. 
[64] F. Yu, L. Sun, K. Machaca, Orai1 internalization and STIM1 clustering inhibition 
modulate SOCE inactivation during meiosis, Proceedings of the National Academy of 












[65] F. Yu, L. Sun, K. Machaca, Constitutive recycling of the store-operated Ca2+ channel 
Orai1 and its internalization during meiosis, The Journal of cell biology, 191 (2010) 523-535. 
[66] B. Zeng, G.L. Chen, E. Garcia-Vaz, S. Bhandari, N. Daskoulidou, L.M. Berglund, H. 
Jiang, T. Hallett, L.P. Zhou, L. Huang, Z.H. Xu, V. Nair, R.G. Nelson, W. Ju, M. Kretzler, 
S.L. Atkin, M.F. Gomez, S.Z. Xu, ORAI channels are critical for receptor-mediated 
endocytosis of albumin, Nat Commun, 8 (2017) 1920. 
[67] T.K. Kim, J.H. Nam, W.G. Ahn, N.H. Kim, H.Y. Ham, C.W. Hong, J.S. Nam, J. Lee, 
S.O. Huh, I. So, S.J. Kim, D.K. Song, Lys1110 of TRPM2 is critical for channel activation, 
Biochem J, 455 (2013) 319-327. 
[68] F. Li, N. Abuarab, A. Sivaprasadarao, Reciprocal regulation of actin cytoskeleton 
remodelling and cell migration by Ca2+ and Zn2+: role of TRPM2 channels, Journal of cell 
science, 129 (2016) 2016-2029. 
[69] S.S. Manji, N.J. Parker, R.T. Williams, L. van Stekelenburg, R.B. Pearson, M. Dziadek, 
P.J. Smith, STIM1: a novel phosphoprotein located at the cell surface, Biochimica et 
biophysica acta, 1481 (2000) 147-155. 
[70] O. Mignen, J.L. Thompson, T.J. Shuttleworth, STIM1 regulates Ca2+ entry via 
arachidonate-regulated Ca2+-selective (ARC) channels without store depletion or 
translocation to the plasma membrane, J Physiol, 579 (2007) 703-715. 
[71] I. Grigoriev, S.M. Gouveia, B. van der Vaart, J. Demmers, J.T. Smyth, S. Honnappa, D. 
Splinter, M.O. Steinmetz, J.W. Putney, Jr., C.C. Hoogenraad, A. Akhmanova, STIM1 is a 
MT-plus-end-tracking protein involved in remodeling of the ER, Curr Biol, 18 (2008) 177-
182. 
[72] S. Maschalidi, P. Nunes-Hasler, C.R. Nascimento, I. Sallent, V. Lannoy, M. Garfa-
Traore, N. Cagnard, F.E. Sepulveda, P. Vargas, A.M. Lennon-Dumenil, P. van Endert, T. 
Capiod, N. Demaurex, G. Darrasse-Jeze, B. Manoury, UNC93B1 interacts with the calcium 
sensor STIM1 for efficient antigen cross-presentation in dendritic cells, Nat Commun, 8 
(2017) 1640. 
[73] R. Hodeify, S. Selvaraj, J. Wen, A. Arredouani, S. Hubrack, M. Dib, S.N. Al-Thani, T. 
McGraw, K. Machaca, A STIM1-dependent 'trafficking trap' mechanism regulates Orai1 
plasma membrane residence and Ca(2)(+) influx levels, Journal of cell science, 128 (2015) 
3143-3154. 
[74] S.W. Park, Y. Zhou, J. Lee, U. Ozcan, Sarco(endo)plasmic reticulum Ca2+-ATPase 2b 
is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity, 
Proceedings of the National Academy of Sciences of the United States of America, 107 
(2010) 19320-19325. 
[75] B. Yang, C. Yang, P. Wang, J. Li, H. Huang, Q. Ji, J. Liu, Z. Liu, Food allergen--
induced mast cell degranulation is dependent on PI3K-mediated reactive oxygen species 
production and upregulation of store-operated calcium channel subunits, Scand J Immunol, 
78 (2013) 35-43. 
[76] P. Lai, F. Michelangeli, Bis(2-hydroxy-3-tert-butyl-5-methyl-phenyl)-methane (bis-
phenol) is a potent and selective inhibitor of the secretory pathway Ca(2)(+) ATPase 
(SPCA1), Biochemical and biophysical research communications, 424 (2012) 616-619. 
 












Fig. 1. Western blot images for calreticulin, plasma membrane (Ca2+ + Mg2+)ATP-ase, 
STIM1 and Orai1 in microsomal fractions derived from the endoplasmic reticulum and 
plasma membrane, showing linearity of band intensity with amount of protein applied to the 
gel. Each panel shows the western blot image for a range of amounts of protein applied to 
each lane (indicated below the lane) and a plot of band intensity as a function of amount of 
protein applied to the gel for calreticulin (A), plasma membrane (Ca2+ + Mg2+)ATP-ase 
(PMCA) (B), STIM1 (C) and Orai1 (D). The subcellular fractions subject to western blot 
were the heavy microsomal fraction (A-C) and PM fraction (D). The results are the means ± 
SEM obtained from the analysis of 4-5 western blots. The lines were drawn on the basis of a 
linear regression analysis. The entire western blot images are shown in Supplemental Data 
Fig. S1. 
 
Fig. 2. Distribution of calreticulin and plasma membrane (Ca2+ + Mg2+)ATP-ase in 
subcellular fractions of untreated rat liver. A,B. Western blot images showing calreticulin 
(Cal) (50 kDa) and (Ca2+ + Mg2+)ATP-ase (PMCA) (150 kDa) in whole liver and in 
subcellular fractions derived from the “Plasma Membrane and Microsomal Fractionation” 
(A) and the “Mitochondria, Microsomal and Cytosolic Fractionation” (B). WL, whole liver; 
LSP, low speed pellet; Mit, mitochondria; HM, heavy microsomes; LM light microsomes; 
and Cyt, cytosol. The images shown are representative of those obtained in 4-6 experiments. 
C-E. Enrichment of calreticulin (C,D) and PMCA (E) in subcellular fractions from the 
“Plasma Membrane and Microsomal Fractionation” (C and E) and the “Mitochondria, 
Microsomal and Cytosolic Fractionation” (D). The “Plasma Membrane and Microsomal 
Fractionation” and the “Mitochondria, Microsomal and Cytosolic Fractionation” were 
conducted as described in Materials and methods.   Results, expressed as band intensity 












blots of subcellular fractions derived from 4-6 separate livers. Degrees of significance in C, D 
and E for comparison of band intensity in a given subcellular fraction with that in WL are:  * 
P<0.05, ** P<0.01, and *** P<0.001. The entire western blot images are shown in 
Supplemental Data Fig. S2. 
 
Fig. 3. Distribution of STIM1 in subcellular fractions of rat liver. A. Western blots showing 
STIM1 (75 kDa) in whole liver and in subcellular fractions derived from the “Plasma 
Membrane and Microsomal Fractionation” (upper panel) and the “Mitochondria, Microsomal 
and Cytosolic Fractionation” (lower panel) of untreated and phenylephrine-treated livers. 
WL, whole liver; LSP, low speed pellet; Mit, mitochondria; HM, heavy microsomes; LM 
light microsomes; and Cyt, cytosol. The images shown are representative of those obtained in 
4-7 experiments. B,C Enrichment of STIM1 in subcellular fractions derived from the 
“Plasma Membrane and Microsomal Fractionation” (B) and the “Mitochondria, Microsomal 
and Cytosolic Fractionation” (C ) from untreated and phenylephrine-treated livers. The 
“Plasma Membrane and Microsomal Fractionation” and the “Mitochondria, Microsomal and 
Cytosolic Fractionation” were conducted as described in Materials and methods.   Results, 
expressed as band intensity (arbitrary units) per mg protein, are the means ± SEM obtained 
from western blots of subcellular fractions derived from 4-7 separate livers. Degrees of 
significance for comparison of band intensity in a given subcellular fraction with that in WL 
are:  * P<0.05. The entire western blot images are shown in Supplemental Data Fig. S3. 
 
Fig. 4. Distribution of Orai1 in subcellular fractions of rat liver. A. Western blot showing 
Orai1 (45 kDa) in whole liver and in subcellular fractions derived from the “Plasma 
Membrane and Microsomal Fractionation” of untreated liver. WL, whole liver; HM, heavy 












in 4-6 experiments. B. Enrichment of Orai1 in subcellular fractions derived from the “Plasma 
Membrane and Microsomal Fractionation” of untreated and phenylephrine-treated livers. The 
“Plasma Membrane and Microsomal Fractionation” and the “Mitochondria, Microsomal and 
Cytosolic Fractionation” were conducted as described in Materials and methods.   Results, 
expressed as band intensity (arbitrary units) per mg protein, are the means ± SEM obtained 
from western blots of subcellular fractions derived from 4-7 separate livers. Degrees of 
significance in B for comparison of band intensity in a given subcellular fraction with that in 
WL are:  * P<0.05, and ** P<0.01. The entire western blot image is shown in Supplemental 
Data Fig. S4. 
 
Fig. 5. Distribution of TRPM2 and Ca2+ ATP-ases 1 and 2 in subcellular fractions of rat liver. 
A. Western blot showing TRPM2 (150 kDa) in whole liver and in subcellular fractions 
derived from the “Mitochondria, Microsomal and Cytosolic Fractionation” of untreated 
livers. WL, whole liver; LSP, low speed pellet; Mit, mitochondria; HM, heavy microsomes; 
LM light microsomes; and Cyt, cytosol. The image shown is representative of that obtained 
in one of three experiments. B. Enrichment of TRPM2 in subcellular fractions derived from 
the “Mitochondria, Microsomal and Cytosolic Fractionation” from untreated livers. The 
results are expressed as intensity (arbitrary units) of the TRPM2 150 kDa band for a given 
subcellular fraction (30 g protein per lane) and are the means ± SEM obtained from western 
blots of subcellular fractions derived from 3 separate livers. C. Western blot showing SPCA1 
(about 100 kDa) and SPCA2 (about 110 kDa) in subcellular fractions derived from the 
“Mitochondria, Microsomal and Cytosolic Fractionation” of untreated liver. HM, heavy 
microsomes; LM, light microsomes and Cyt, cytosol. The “Mitochondria, Microsomal and 
Cytosolic Fractionation” was conducted as described in Materials and methods.   The images 












for comparison of band intensity in a given subcellular fraction with that in WL are:  ** 
P<0.01. 
 
Fig. 6. Immunoprecipitation of STIM1 from the heavy microsomal fraction and identification 
of peroxiredoxin-4 in the immunoprecipitate. A. Western blot of STIM1 (75 kDa) in the 
precipitate resulting from the immunoprecipitation of STIM1 from the heavy microsomal 
subcellular fraction prepared from untreated livers. STIM1 was immunoprecipitated using an 
anti-STIM1 antibody (Abcam, # 52458), and identified in the western blot using the same 
anti-STIM1 antibody. B. Western blot identifying peroxiredoxin-4 (Prx-4) (monomer 25 kDa 
and dimer 50 kDa) in in whole liver (WL) and the low speed pellet (LSP), mitochondrial 
(Mt), heavy microsomal (HM), light microsomal (LM) and cytosolic (Cyt) subcellular 
fractions. C. Enrichment of Prx-4 in subcellular fractions derived from the “Mitochondria, 
Microsomal and Cytosolic Fractionation” from untreated livers.  LSP, low speed pellet. 
Results are expressed as the sum of the intensities of the 25 and 50 kDa bands (arbitrary units 
of band intensity for 30 g protein applied per lane), relative to that of the band for whole 
liver, and are the means ± SEM obtained from western blots of subcellular fractions derived 
from three separate livers. D. Western blot of Prx-4 (25 and 50 kDa) in the precipitate 
resulting from the immunoprecipitation of STIM1 from the heavy microsomal subcellular 
fraction prepared from untreated livers. STIM1 was immunoprecipitated (anti-STIM1 
antibody Abcam, # 52458) and Prx-4 detected using anti-Prx-4 antibody (Biosensis, # R-
1593-100). E. Knockdown of Prx-4 using siRNA targeted against Prx-4 in H4IIE rat liver 
cells. The amount of protein added to each lane for control cells (No siRNA), cells incubated 
with scrambled siRNA (siCtl) and with siRNA targeted against Prx-4 (siPrx-4) is indicated 
under each lane. Quantitation of band intensities gave values of 79, 77, and 80 % for the 












protein per lane, respectively. The western blot images in A,B and D and E are representative 
of those obtained in three experiments which each gave similar results. Degrees of 
significance in C for comparison of band intensity in a given subcellular fraction with that in 
WL, and for comparison of HM with LM, are:  * P<0.05 and *** P<0.001. 
Fig. 7. Effects of knockdown of Prx-4 on store-operated Ca2+ entry measured in the absence 
and presence of hydrogen peroxide. A-D. Representative traces showing the effects of the 
addition of DBHQ in the absence of added extracellular Ca2+ (Ca2+ext) and the subsequent 
addition of 2.4 mM Ca2+ext on [Ca
2+]cyt, in H4IIE rat liver cells incubated with scrambled 
siRNA (Control siRNA) (A,B) or siRNA targeted against Prx-4 (Prx-4 siRNA) (C,D) in the 
absence (A,C) and presence (B,D) of H2O2. E,F. Amounts of Ca
2+ released by DBHQ (peak 
height), and initial rates of Ca2+ entry following Ca2+ext addition, respectively (means ± SEM 
(n = 3 independent experiments)). Degrees of significance: * P<0.05.  
Fig. 8. Effects of Conoidin A, an inhibitor of Prx-4, on store-operated Ca2+ entry measured in 
the absence and presence of hydrogen peroxide. A-D. Representative traces showing the 
effects of the addition of DBHQ in the absence of added extracellular Ca2+ (Ca2+ext) and the 
subsequent addition of 2.4 mM Ca2+ext on [Ca
2+]cyt, in H4IIE rat liver cells pre-incubated for 
24 h in the absence (A,B) or presence (C,D) of 50 M Conoidin A, and in the absence (A,C) 
and presence (B,D) of H2O2. E,F. Amounts of Ca
2+ released by DBHQ (peak height), and 
initial rates of Ca2+ entry following Ca2+ext addition, respectively (means ± SEM (n = 3 












Fig. 9. Schematic representation of the hypothesised role(s) of peroxiredoxin-4 (Prx4) in 
regulating the activation of store-operated Ca2+ entry in hepatocytes. Following the release of 
Ca2+ from the cEF binding site of STIM1 in the lumen of the ER, and subsequent changes in 
conformation, STIM1 interacts with Orai1 and activates the SOCE [1]. It is hypothesised that 
Prx-4 binds to STIM1 and may regulate the folding of STIM1 in the ER (1) and/or may simply 
remove ROS and prevent ROS-induced inhibition of STIM1 (2). PDI, protein disulphide 






















































































































Table 1.  












Protein bands detected 
(estimated size of the 
band)  
Reference to expected 












(Fig. 1A, 2A, 
Supplemental Data 

















160 kDa (major band) 
140 kDa (weak band) 
(Fig. 1B, 2A,  
Supplemental  Data 
Figs.S1 and S2.) 
The 160 kDa band was 
















Table 2.  
Distribution of STIM1 and Orai1 in subcellular fractions derived from untreated and 
phenylephrine-treated livers.  
aResults, expressed as band intensity (arbitrary units) per total volume of the given fraction, 
are the means ± SEM obtained from western blots of subcellular fractions derived from 5-6 













(Fig. 3A,  











1:500 Donkey anti 
rabbit-HRP 
1:5000 
45 kDa (glycosylated 
Orai1) 













1:1000 Donkey anti 
rabbit-HRP 
1:5000 
25 kDa (monomer) 
and 50 kDa (dimer) 
(Fig. 6B) 
The sum of the 25 and 
50 kDa bands was 




















Santa Cruz #sc 
Dallas, Texas, 
USA -134450 
1:350 Donkey Anti 
Rabbit-HRP 
1:2000 
100 kDa SPCA 1)  


















Amount of STIM1 in each fractiona Amount of Orai11 in each fractiona 
Untreated liver Phenylephrine-treated 
liver 




































-3.6±19 100 17±47 100 9.0±2.9 100 83±36 100 
Heavy 
microsomes 
39±17 85 50.1±29 76 3.9±0.8 44 39±0.8 45 
Light 
microsomes 
5.6±2.0 12.5 16.1±3.2 24 2.4±2.6 27 3.9±0.8 27 
Plasma 
membrane 


















Table 3.   
Proteins detected by LC/MS in the precipitate resulting from the 
immunoprecipitation of STIM1 from the heavy microsomal subcellular fraction 
prepared from untreated livers. 
a Calculated percentage of the protein sequence determined from the individual 
unique peptides. b Number of unique peptide matches with the protein sequence. 
cThe results shown were obtained following the analysis of proteins in the 
precipitates obtained from the immunoprecipitation of STIM1 from heavy 



























































Score Protein Namec 
P84903 25.55 15 79.86 Stromal interaction molecular 1(STIM1) 
D4ABS3 36.96 5 58.74 HistoneH2B 
P20762 14.29 4 44.99 Ig gamma-2C chain C region 
Q9Z0V5 21.98 5 31.65 Peroxiredoxin-4 
Q5BJT0 11.44 4 18.02 Arginine and glutamate protein 1 
Q6IFU7 11.06 4 15.47 Keratin, type I cytoskeletal 42 
Q6IFU9 9.72 3 13.81 ProteinKrt16 
Q6AXS5-2 6.89 2 10.19 Isoform 2 od plasminogen activator inhibitor 
1 RNA-binding protein 
F1M7H9 7.58 2 9.75 Protein Luc712 (Fragment) 
B2RZB7 20.17 2 7.53 Protein Snrpd1 
P02600-2 16.00 2 5.91 Isoform MLC3 Myosin light chain 1/3, 
skeleton muscle isoform 
F1LRK8 4.56 2 5.08 Actin-related protein 3 
D4A1G4 30.00 2 4.86 Cytochrome b5 
B5DES0 16.10 2 4.20 Protein Snrpd2 
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